ºÚÁÏÉç

After nearly three years of backorders and pharmacy scrambles, the high-demand weight-loss drugs Ozempic, Wegovy, and Mounjaro are finally back in full supply. The FDA recently declared an end to the nationwide shortage of their active ingredients, semaglutide and tirzepatide. Martin Binks, chair of the Department of Nutrition and Food Studies at ºÚÁÏÉç and a researcher and clinician with expertise in obesity, explains what this moment means for patients, providers, and public health.

Why Front-Loading Calories May Not Help You Lose Weight